Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when
given together with bortezomib in treating patients with relapsed or refractory lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Brian Hill, MD, PhD
Collaborators:
National Cancer Institute (NCI) The Leukemia and Lymphoma Society